Company Overview
About Paradromics
Paradromics is a neurotechnology company based in Austin, Texas, focused on developing brain-computer interface (BCI) technology specifically for restoring communication and independence to patients with severe paralysis caused by ALS, stroke, and spinal cord injury. The company's lead product, the Connexus BCI, is a fully implantable neural interface system designed to record high-resolution neural signals from the motor cortex and decode them into speech output — enabling patients who have lost the ability to speak or move to communicate through their thoughts.
Business Model & Competitive Advantage
Paradromics has achieved two major regulatory milestones. The FDA granted the company Breakthrough Medical Device Designation for the Connexus system, and in November 2025 awarded an Investigational Device Exemption (IDE) approval for the Connect-One Early Feasibility Study — making Paradromics the first company to receive IDE approval for speech restoration with a fully implantable BCI. In May 2026, the company completed the first successful human implantation of the Connexus BCI at the University of Michigan, entering clinical-stage operations. The company has raised over $105M in total funding, including $88.7M in venture capital across 13 rounds from 28 investors (led by Prime Movers Lab, with Westcott Investment Group, Dolby Family Ventures, and Green Sands Equity) plus approximately $18M in grants from the National Institutes of Health (NIH) and DARPA.
Competitive Landscape 2025–2026
Paradromics competes in the emerging BCI space alongside Neuralink (which has implanted more patients but focuses on a broader general-purpose BCI) and Synchron (which uses a minimally invasive endovascular approach). Paradromics differentiates through its focus on high-density neural recording (enabling high-resolution speech decoding) and its clinical regulatory pathway specifically targeting speech restoration.
Key Differentiators
Emerging Innovator
Paradromics is an emerging player bringing innovative solutions to the Life Sciences & BioTech market.
Frequently Asked Questions
Similar Brands
Neuralink
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with pa
Pliant Therapeutics
Pliant Therapeutics develops small molecule integrin inhibitors targeting the pathological tissue scarring (fibrosis) that drives diseases including idiopathic pulmonary fibrosis (IPF), primary sclero
Illumina
Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applicat
Cradle
Cradle is a protein design platform using AI to help biotechnology and pharmaceutical companies engineer better proteins — enzymes, antibodies, and therapeutic proteins — with improved stability, acti
BioNTech
BioNTech SE was founded in 2008 in Mainz, Germany by Ugur Sahin, Ozlem Tureci, and Christoph Huber with a mission to harness the immune system for individualized cancer treatment. The company pioneere
Genentech
Genentech was founded in 1976 in South San Francisco by Herbert Boyer and Robert Swanson, becoming the first company to produce human insulin using recombinant DNA technology and essentially launching
Compare Paradromics with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Paradromics? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Paradromics Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Paradromics vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →